Argenx US, Inc.
Boston, MA
- UEI
- YQQMVL36XZ11
- CAGE
- 94MS5
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 33 Arch St 32Nd Fl Ste 3201, Boston, MA 02110, USA
- Website
- argenx.com
- Founded
- 2008
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract vehicles
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Botanix SB Inc. | Phoenix, AZ | 325412 Pharmaceutical Preparation Manufacturing |
| Takeda Pharmaceuticals America, Inc. | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Arrowhead Pharmaceuticals, Inc. | Pasadena, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Merz Pharmaceuticals, LLC | Raleigh, NC | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Argenx US, Inc., a foreign-owned pharmaceutical manufacturer headquartered in Boston, Massachusetts, supplies branded pharmaceutical products to the Department of Veterans Affairs as a prime contractor under GSA Federal Supply Schedule agreements, with no subcontractor activity in recent federal work. The vendor operates exclusively in full-and-open competition with no set-aside designations across its federal portfolio.
Argenx's federal footprint centers on a single pharmaceutical product. The National Acquisition Center established a single-award Blanket Purchase Agreement with Argenx on September 12, 2026, for Vyvgart Hytrulo under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), carrying a $703.3 million ceiling and an ultimate completion date of September 11, 2027. This represents the vendor's dominant federal commitment by dollar value. Earlier work included a multiple-award Federal Supply Schedule contract awarded August 1, 2022, to Veterans Integrated Service Network 12 (a civilian healthcare delivery network within the Department of Veterans Affairs) for pharmaceutical and hematology-related products, with a $225 thousand ceiling and an ultimate completion date of July 31, 2027; this award incorporated a permanent Federal Contractor Partnership framework. A third award—an interim FSS agreement with VISN 12 awarded March 4, 2022, with a $25 thousand ceiling—was cancelled by August 2022.
Customer concentration is entirely within the Department of Veterans Affairs. The National Acquisition Center anchors 99.9% of combined potential value ($703.3 million of $703.5 million total), while VISN 12 accounts for two awards representing $250 thousand in combined potential value. All three awards operate under the Pharmaceuticals and Drugs FSS schedule. The vendor's primary NAICS category is Pharmaceutical Preparation Manufacturing, with task order activity classified under Drugs and Biologicals and Medicated Cosmetics and Toiletries PSCs. The Vyvgart Hytrulo BPA completes September 11, 2027, representing a single recompete opportunity within the next twelve months.
Quick answers
Is Argenx US, Inc. registered in SAM.gov?
Yes. Argenx US, Inc.'s SAM.gov registration is active through November 19, 2026.
Which contract vehicles does Argenx US, Inc. hold?
Argenx US, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
On GovTribe
See Argenx US, Inc.'s full federal record
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors